These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1019 related articles for article (PubMed ID: 34431693)

  • 41. Persistence of Neutralizing Antibodies to SARS-CoV-2 in First Wave Infected Individuals at Ten Months Post-Infection: The UnIRSA Cohort Study.
    Griffante G; Chandel S; Ferrante D; Caneparo V; Capello D; Bettio V; Borgogna C; Aleni C; Esposito S; Sarro A; Vasile A; Comba M; Testa T; Cotrupi G; De Andrea M; Bortoluzzi S; Gariglio M
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835076
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Original antigenic sin responses to Betacoronavirus spike proteins are observed in a mouse model, but are not apparent in children following SARS-CoV-2 infection.
    Lapp SA; Edara VV; Lu A; Lai L; Hussaini L; Chahroudi A; Anderson LJ; Suthar MS; Anderson EJ; Rostad CA
    PLoS One; 2021; 16(8):e0256482. PubMed ID: 34449792
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection.
    Pradenas E; Trinité B; Urrea V; Marfil S; Tarrés-Freixas F; Ortiz R; Rovirosa C; Rodon J; Vergara-Alert J; Segalés J; Guallar V; Valencia A; Izquierdo-Useros N; Noguera-Julian M; Carrillo J; Paredes R; Mateu L; Chamorro A; Toledo R; Massanella M; Clotet B; Blanco J
    Cell Rep Med; 2022 Feb; 3(2):100523. PubMed ID: 35233547
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patients.
    Chansaenroj J; Yorsaeng R; Puenpa J; Wanlapakorn N; Chirathaworn C; Sudhinaraset N; Sripramote M; Chalongviriyalert P; Jirajariyavej S; Kiatpanabhikul P; Saiyarin J; Soudon C; Thienfaidee O; Ayuthaya TPN; Brukesawan C; Intharasongkroh D; Chaiwanichsiri D; Issarasongkhram M; Kitphati R; Mungaomklang A; Thitithanyanont A; Nagavajara P; Poovorawan Y
    PLoS One; 2022; 17(4):e0267102. PubMed ID: 35446889
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Seroconversion and Abundance of IgG Antibodies against S1-RBD of SARS-CoV-2 and Neutralizing Activity in the Chilean Population.
    González-Stegmaier R; Cereceda K; Briones JL; Beltran-Pávez C; Oyarzún-Arrau A; Riquelme-Barrios S; Selman C; Yarad F; Mahave M; Caglevic C; Morales R; Aguirre A; Valiente-Echeverría F; Soto-Rifo R; Marsiglia H; Gazitua R; Villarroel-Espindola F
    J Immunol Res; 2021; 2021():6680337. PubMed ID: 33644235
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
    Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
    Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sex Differences in Lung Imaging and SARS-CoV-2 Antibody Responses in a COVID-19 Golden Syrian Hamster Model.
    Dhakal S; Ruiz-Bedoya CA; Zhou R; Creisher PS; Villano JS; Littlefield K; Ruelas Castillo J; Marinho P; Jedlicka AE; Ordonez AA; Bahr M; Majewska N; Betenbaugh MJ; Flavahan K; Mueller ARL; Looney MM; Quijada D; Mota F; Beck SE; Brockhurst J; Braxton AM; Castell N; Stover M; D'Alessio FR; Metcalf Pate KA; Karakousis PC; Mankowski JL; Pekosz A; Jain SK; Klein SL;
    mBio; 2021 Aug; 12(4):e0097421. PubMed ID: 34253053
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neutralizing Antibody Responses to SARS-CoV-2 in Recovered COVID-19 Patients Are Variable and Correlate With Disease Severity and Receptor-Binding Domain Recognition.
    Maciola AK; La Raja M; Pacenti M; Salata C; De Silvestro G; Rosato A; Pasqual G
    Front Immunol; 2022; 13():830710. PubMed ID: 35173741
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Correlation of humoral immune responses to different SARS-CoV-2 antigens with virus neutralizing antibodies and symptomatic severity in a German COVID-19 cohort.
    Rockstroh A; Wolf J; Fertey J; Kalbitz S; Schroth S; Lübbert C; Ulbert S; Borte S
    Emerg Microbes Infect; 2021 Dec; 10(1):774-781. PubMed ID: 33830901
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma.
    Natarajan H; Crowley AR; Butler SE; Xu S; Weiner JA; Bloch EM; Littlefield K; Wieland-Alter W; Connor RI; Wright PF; Benner SE; Bonny TS; Laeyendecker O; Sullivan D; Shoham S; Quinn TC; Larman HB; Casadevall A; Pekosz A; Redd AD; Tobian AAR; Ackerman ME
    mBio; 2021 Apr; 12(2):. PubMed ID: 33879585
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection.
    Gharbharan A; Jordans CCE; GeurtsvanKessel C; den Hollander JG; Karim F; Mollema FPN; Stalenhoef-Schukken JE; Dofferhoff A; Ludwig I; Koster A; Hassing RJ; Bos JC; van Pottelberge GR; Vlasveld IN; Ammerlaan HSM; van Leeuwen-Segarceanu EM; Miedema J; van der Eerden M; Schrama TJ; Papageorgiou G; Te Boekhorst P; Swaneveld FH; Mueller YM; Schreurs MWJ; van Kampen JJA; Rockx B; Okba NMA; Katsikis PD; Koopmans MPG; Haagmans BL; Rokx C; Rijnders BJA
    Nat Commun; 2021 May; 12(1):3189. PubMed ID: 34045486
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients.
    Luchsinger LL; Ransegnola BP; Jin DK; Muecksch F; Weisblum Y; Bao W; George PJ; Rodriguez M; Tricoche N; Schmidt F; Gao C; Jawahar S; Pal M; Schnall E; Zhang H; Strauss D; Yazdanbakhsh K; Hillyer CD; Bieniasz PD; Hatziioannou T
    J Clin Microbiol; 2020 Nov; 58(12):. PubMed ID: 32917729
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2.
    Vanhove B; Duvaux O; Rousse J; Royer PJ; Evanno G; Ciron C; Lheriteau E; Vacher L; Gervois N; Oger R; Jacques Y; Conchon S; Salama A; Duchi R; Lagutina I; Perota A; Delahaut P; Ledure M; Paulus M; So RT; Mok CK; Bruzzone R; Bouillet M; Brouard S; Cozzi E; Galli C; Blanchard D; Bach JM; Soulillou JP
    Eur J Immunol; 2021 Jun; 51(6):1412-1422. PubMed ID: 33576494
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities.
    Noval MG; Kaczmarek ME; Koide A; Rodriguez-Rodriguez BA; Louie P; Tada T; Hattori T; Panchenko T; Romero LA; Teng KW; Bazley A; de Vries M; Samanovic MI; Weiser JN; Aifantis I; Cangiarella J; Mulligan MJ; Desvignes L; Dittmann M; Landau NR; Aguero-Rosenfeld M; Koide S; Stapleford KA
    Sci Rep; 2021 Mar; 11(1):5538. PubMed ID: 33692390
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers, and convalescent plasma donors.
    Zeng C; Evans JP; Pearson R; Qu P; Zheng YM; Robinson RT; Hall-Stoodley L; Yount J; Pannu S; Mallampalli RK; Saif L; Oltz E; Lozanski G; Liu SL
    JCI Insight; 2020 Nov; 5(22):. PubMed ID: 33035201
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers.
    Irsara C; Egger AE; Prokop W; Nairz M; Loacker L; Sahanic S; Pizzini A; Sonnweber T; Holzer B; Mayer W; Schennach H; Loeffler-Ragg J; Bellmann-Weiler R; Hartmann B; Tancevski I; Weiss G; Binder CJ; Anliker M; Griesmacher A; Hoermann G
    Clin Chem Lab Med; 2021 Jul; 59(8):1453-1462. PubMed ID: 33837679
    [TBL] [Abstract][Full Text] [Related]  

  • 58. SARS-CoV-2 Infection of Rhesus Macaques Treated Early with Human COVID-19 Convalescent Plasma.
    Deere JD; Carroll TD; Dutra J; Fritts L; Sammak RL; Yee JL; Olstad KJ; Reader JR; Kistler A; Kamm J; Di Germanio C; Shaan Lakshmanappa Y; Elizaldi SR; Roh JW; Simmons G; Watanabe J; Pollard RE; Usachenko J; Immareddy R; Schmidt BA; O'Connor SL; DeRisi J; Busch MP; Iyer SS; Van Rompay KKA; Hartigan-O'Connor DJ; Miller CJ
    Microbiol Spectr; 2021 Dec; 9(3):e0139721. PubMed ID: 34817208
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
    Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
    Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Virological Characterization of Critically Ill Patients With COVID-19 in the United Kingdom: Interactions of Viral Load, Antibody Status, and B.1.1.7 Infection.
    Ratcliff J; Nguyen D; Fish M; Rynne J; Jennings A; Williams S; Al-Beidh F; Bonsall D; Evans A; Golubchik T; Gordon AC; Lamikanra A; Tsang P; Ciccone NA; Leuscher U; Slack W; Laing E; Mouncey PR; Ziyenge S; Oliveira M; Ploeg R; Rowan KM; Shankar-Hari M; Roberts DJ; Menon DK; Estcourt L; Simmonds P; Harvala H;
    J Infect Dis; 2021 Aug; 224(4):595-605. PubMed ID: 34031695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.